米国企業
Theravance Biopharma, Inc.

Theravance Biopharma, Inc.TBPH

時価総額

$4.5億

PER

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Cash and cash equivalents	89	113	345	89	378	58	81	90	298	40
Short-term marketable securities	165	60	156	260	127	223	211	84	29	63
Receivables from Collaboration Partners	2	35	9	7	10	12	16	14	17	17
Prepaid clinical and development services	-	-	-	-	-	-	20	10	2	2
Other Prepaid Expense, Current	-	5	2	4	17	7	10	9	8	12
Total current assets	275	237	529	379	533	338	393	250	353	134
Total current assets	275	237	529	379	533	338	393	250	353	134
Property and equipment, net	10	10	8	10	13	13	16	14	12	9
Operating lease assets	-	-	-	-	-	47	43	40	40	36
Future contingent milestone and royalty assets	-	-	-	-	-	-	-	-	194	194
Restricted cash	-	-	-	-	-	1	1	1	1	1
Other assets	1	1	2	2	2	2	2	3	7	8
Total assets	338	300	639	441	560	409	469	375	607	382
Total assets	338	300	639	441	560	409	469	375	607	382
Accounts payable	10	19	2	6	9	5	7	3	2	2
Accrued personnel-related expenses	18	11	14	24	24	28	35	13	10	6
Accrued clinical and development expenses	-	15	25	21	12	18	29	17	5	2
Accrued general and administrative expenses	-	-	-	-	-	-	6	3	4	3
Operating lease liabilities	-	-	-	-	-	8	10	1	7	4
Deferred revenue	-	-	-	-	43	32	12	0	0	-
Tenant Improvement Payable Current	-	-	-	-	-	-	-	-	-	6
Other accrued liabilities	8	5	8	12	10	6	2	1	1	1
Accrued interest payable	-	-	-	-	-	6	4	4	-	-
Total current liabilities	41	49	49	63	99	112	124	59	29	25
Total current liabilities	41	49	49	63	99	112	124	59	29	25
Long-term operating lease liabilities	-	-	-	-	-	48	47	53	45	45
Future royalty payment contingency	-	-	-	-	-	-	-	-	25	28
Long-term deferred revenue	-	-	-	-	26	7	0	0	0	-
Unrecognized tax benefits	-	-	-	-	-	-	-	-	64	65
Other long-term liabilities	2	3	13	36	25	21	2	2	2	6
Convertible Notes Payable, Noncurrent	-	-	223	224	225	226	227	228	-	-
Non-recourse notes due 2035, net	-	-	-	-	-	-	373	371	-	-
Common Stock, Value, Issued	-	-	0	0	0	0	0	0	0	-
Additional paid-in capital	429	565	863	914	961	1,025	1,223	1,387	1,296	1,122
Accumulated other comprehensive loss	-0	-0	-0	-1	-0	0	0	-	-0	-0
Accumulated deficit	-139	-322	-512	-798	-1,012	-1,249	-1,527	-1,726	-854	-909
Total shareholders' equity	290	243	350	115	-52	-224	-304	-339	442	213
Total liabilities and shareholders' equity	338	300	639	441	560	409	469	375	607	382
Common Stock, Value, Issued	-	-	0	0	0	0	0	0	0	-
Additional paid-in capital	429	565	863	914	961	1,025	1,223	1,387	1,296	1,122
Accumulated other comprehensive loss	-0	-0	-0	-1	-0	0	0	-	-0	-0
Accumulated deficit	-139	-322	-512	-798	-1,012	-1,249	-1,527	-1,726	-854	-909
Total shareholders' equity	290	243	350	115	-52	-224	-304	-339	442	213
Total liabilities and shareholders' equity	338	300	639	441	560	409	469	375	607	382